The stock's overall trend over the past six months has been negative, declining 5.56% from October 2025 to the current price of $11.54. The price peaked near $14.43 in late February 2026 before a sharp correction. Short-term performance has been particularly weak, with the stock down 18.10% over the past month, significantly underperforming the S&P 500, which fell only 5.25% over the same period. The 3-month performance is also negative, down 12.04%, compared to a 4.63% decline for the S&P 500. The current price of $11.54 is positioned in the lower half of its 52-week range of $8.44 to $14.80. The stock is approximately 22% below its 52-week high and 37% above its 52-week low, indicating it has retreated substantially from recent highs.

Revenue and profitability have shown significant volatility. The latest Q4 2025 revenue of $45.89 billion declined 4.81% year-over-year, and the quarter resulted in a substantial net loss of -$11.06 billion, translating to a net margin of -24.1%. This contrasts sharply with the profitable Q3 2025, which had a net margin of 4.8%. The company's financial health is a concern, with a very high debt-to-equity ratio of 4.66, indicating significant leverage. However, the trailing twelve-month free cash flow is a robust $12.47 billion, providing some liquidity. Operational efficiency metrics are weak, with a negative Return on Equity (ROE) of -22.76% and a negative Return on Assets (ROA) of -0.13%, reflecting poor profitability relative to shareholder equity and total assets.